ALK-Abello A/S
CSE:ALK B

Watchlist Manager
ALK-Abello A/S Logo
ALK-Abello A/S
CSE:ALK B
Watchlist
Price: 223 DKK 2.2%
Market Cap: 45.2B DKK

ALK-Abello A/S
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ALK-Abello A/S
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
ALK-Abello A/S
CSE:ALK B
Cash from Operating Activities
kr1.5B
CAGR 3-Years
47%
CAGR 5-Years
39%
CAGR 10-Years
N/A
Novo Nordisk A/S
CSE:NOVO B
Cash from Operating Activities
kr123.8B
CAGR 3-Years
22%
CAGR 5-Years
17%
CAGR 10-Years
13%
H Lundbeck A/S
CSE:HLUN A
Cash from Operating Activities
kr3.3B
CAGR 3-Years
14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Stenocare A/S
CSE:STENO
Cash from Operating Activities
-kr7.1m
CAGR 3-Years
19%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
No Stocks Found

ALK-Abello A/S
Glance View

Market Cap
49.4B DKK
Industry
Pharmaceuticals

ALK-Abelló A/S is a fascinating player in the global pharmaceutical market, renowned for its dedication to alleviating the impact of allergies through innovative treatments. Born in the heart of Denmark, this company has carved a niche for itself by focusing intensely on developing immunotherapy solutions for allergy sufferers—a sector often overshadowed by more glamorous pharmaceutical pursuits. ALK-Abelló operates at the forefront of the allergen immunotherapy landscape, committed to transforming the lives of those affected by allergic conditions, such as hay fever and allergic asthma. The company's portfolio includes allergy immunotherapy tablets, injection-based treatments, and diagnostic devices designed to offer comprehensive allergy solutions, catering to both established and emerging markets. The essence of ALK-Abelló’s business model lies in its strategic focus on the research, development, and commercialization of allergy immunotherapies. Through rigorous scientific research and development, the company has developed a series of groundbreaking allergy tablets that provide patients with a convenient, effective alternative to traditional injection-based treatments. This innovation not only harnesses scientific advancements but also addresses consumer demand for ease and efficacy. Revenue streams are predominantly generated through the sale of these innovative products to healthcare providers and patients, a process supported by strong partnerships with clinical professionals and an extensive distribution network. In essence, ALK-Abelló finds its competitive edge in delivering tailored, cutting-edge allergy treatments that not only improve patient outcomes but also promise to reduce the long-term economic burden of allergic diseases.

ALK B Intrinsic Value
197.93 DKK
Overvaluation 11%
Intrinsic Value
Price

See Also

What is ALK-Abello A/S's Cash from Operating Activities?
Cash from Operating Activities
1.5B DKK

Based on the financial report for Sep 30, 2025, ALK-Abello A/S's Cash from Operating Activities amounts to 1.5B DKK.

What is ALK-Abello A/S's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
39%

Over the last year, the Cash from Operating Activities growth was 43%. The average annual Cash from Operating Activities growth rates for ALK-Abello A/S have been 47% over the past three years , 39% over the past five years .

Back to Top